pubmed· e01.org

PubMed · PMID 23463520

Is postoperative adjuvant chemoradiotherapy necessary for high-risk oropharyngeal squamous cell carcinoma?

PMID 23463520Journal International journal of clinical oncologyYear 2014Authors 12DOI 10.1007/s10147-013-0532-y

  • Source PubMed
  • Journal International journal of clinical oncology
  • Year 2014
  • Authors Tomoya Yokota; Tetsuro Onitsuka; Kimihide Kusafuka; Hirofumi Ogawa; Yusuke Onozawa; Masahiro Nakagawa; Yoshiyuki Iida; Tomoyuki Kamijo; Tetsuo Nishimura; Takashi Nakajima; Narikazu Boku; Hirofumi Yasui
  • Licence NLM/PubMed terms

Abstract

High-risk factors for recurrence of head and neck squamous cell carcinoma after surgical resection include involvement of ≥ 2 regional lymph nodes, extracapsular spread, and microscopic involvement of resected mucosal margins. Adjuvant chemoradiotherapy is thought to improve postoperative locoregional control and survival. In this paper, we evaluate the efficacy of adjuvant therapy for high-risk oropharyngeal squamous cell carcinoma (OPSCC) (i.e., with ≥ 2 lymph nodes, positive extracapsular spread, or positive margins).

This is a retrospective analysis of 45 high-risk OPSCC patients who underwent surgery without adjuvant therapy (n = 19), with radiotherapy (n = 17), or with chemoradiotherapy (n = 9). The median follow-up period was 41.0 months. Radiotherapy patients showed a trend toward longer overall survival than patients without adjuvant therapy [hazard ratio (HR) = 0.32, p = 0.176]. However, overall survival for the chemoradiotherapy group seemed to be the same as that for the no adjuvant therapy group (HR = 0.79, p = 0.779).

Multivariate analysis found that the relative risk of recurrence for patients without adjuvant therapy compared with any adjuvant therapy was 3.02 (p = 0.101). The relative recurrence risk in radiotherapy patients was 0.95 compared with that in chemoradiotherapy patients (p = 0.971). However, pathological T-stage was significantly associated with disease-free survival for high-risk OPSCC.

Although the current study uses data from a small retrospective sample of patients, our results suggest that the addition of chemotherapy to radiotherapy may not be necessary as an adjuvant therapy for all high-risk OPSCC. A novel prognostic factor, such as pathological T-stage, should be considered for selecting those patients with high-risk OPSCC who would benefit from adjuvant therapy.

Record details

PMID23463520
DOI10.1007/s10147-013-0532-y
JournalInternational journal of clinical oncology
Year2014
AuthorsTomoya Yokota; Tetsuro Onitsuka; Kimihide Kusafuka; Hirofumi Ogawa; Yusuke Onozawa; Masahiro Nakagawa; Yoshiyuki Iida; Tomoyuki Kamijo; Tetsuo Nishimura; Takashi Nakajima; Narikazu Boku; Hirofumi Yasui
MeSHAged; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Postoperative Period; Proportional Hazards Models

Source record

Open the PubMed record. This page reproduces the abstract and citation fields held in the local baseline; it does not rehost the article.

Source
PubMed / NLM
PMID
23463520
Rendered
2026-11-21
Completeness
Abstract and citation fields only; full text is not rehosted.